UNCY FY2024 EPS Boosted by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Brookline Capital Management increased their FY2024 earnings per share (EPS) estimates for Unicycive Therapeutics in a report released on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now anticipates that the company will earn ($0.03) per share for the year, up from their previous estimate of ($0.08). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q4 2024 earnings at ($0.07) EPS and FY2025 earnings at ($0.15) EPS.

Several other equities research analysts also recently weighed in on UNCY. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of Unicycive Therapeutics in a report on Tuesday, November 12th. Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a report on Friday, September 6th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Unicycive Therapeutics presently has an average rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Stock Performance

UNCY stock opened at $0.46 on Monday. The company has a market capitalization of $47.24 million, a P/E ratio of -0.47 and a beta of 2.29. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.82. The business has a 50 day simple moving average of $0.43 and a 200-day simple moving average of $0.54.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds have recently modified their holdings of UNCY. Virtu Financial LLC acquired a new stake in Unicycive Therapeutics in the first quarter valued at $36,000. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics in the third quarter valued at $29,000. Bleakley Financial Group LLC acquired a new stake in Unicycive Therapeutics in the third quarter valued at $33,000. Acuta Capital Partners LLC acquired a new stake in Unicycive Therapeutics in the third quarter valued at $807,000. Finally, BVF Inc. IL lifted its holdings in Unicycive Therapeutics by 70.5% in the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after acquiring an additional 1,493,462 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.